Direct-acting antivirals for HCV-related hepatocellular carc

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

Related Keywords

Osaka , Japan , Barcelona , Comunidad Autonoma De Cataluna , Spain , Sawako Uchida Kobayashi , Norifumi Kawada , Hiroko Ikenaga , Emily Henderson , Department Of Hepatology , Osaka City University Graduate School Of Medicine , Osaka City University Graduate School , Barcelona Clinic Liver Cancer , Lecturer Sawako Uchida Kobayashi , Cancer , Hepatitis , Hepatitis C , Liver , Liver Cancer , Virus , Cancer Treatment , Arcinoma , Hepatocellular Carcinoma , Liver Disease , Medicine , Ortality , Research , Humor ,